Phase III efficiency trial reportedly showed liprotamase improved CF patients’ condition.

Alnara Pharmaceuticals entered a licensing agreement with the Cystic Fibrosis Foundation Therapeutics for the worldwide rights to liprotamase, an oral, porcine-free pancreatic enzyme replacement therapy (PERT). The treatment has completed a Phase III efficiency trial that reportedly showed improvement in fat and protein absorption in CF patients who took liprotamase.

PERT is used to treat the pancreatic insufficiency, common in patients with cystic fibrosis and chronic pancreatitis, which prevents them from properly absorbing nutrients from food.

“Liprotamase has the potential to significantly advance the treatment of pancreatic insufficiency, and Alnara plans to complete development, seek FDA approval, and make it available to patients,” says Alexey Margolin, Ph.D., president and CEO of Alnara.

The Cystic Fibrosis Foundation has reportedly invested more than $300 million in drug research with biotech companies since 1998 for CF treatments.

Previous articleStemgent Inks Deal to Co-Market CellDesign’s Adipocyte Research Products
Next articleNeuraltus Closes $17M Series A Financing